Thyroid Cancer Trial, Recruiting (NCT06863805)

Thyroid Cancer Trial, Recruiting NCT06863805 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Thyroid Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06863805 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Thyroid Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be willing and able to sign a consent form agreeing to take part in the study
You must be an adult aged 18 or older (male or female)
You must have been diagnosed with advanced thyroid cancer, confirmed by a central review of tissue samples
Your thyroid cancer must be one of the following types: well-differentiated thyroid cancer, medullary thyroid cancer, or anaplastic thyroid cancer — and it must be at a stage where doctors are considering starting drug-based treatment
A genetic analysis of your tumor tissue must have already been carried out using a specific type of advanced molecular testing (confirm with trial site)
Your cancer must be measurable on standard imaging scans, such as a CT scan with contrast dye, or a PET-CT scan

Who may not be able to join:

You may not be eligible if you have already received any previous drug-based treatments for your thyroid cancer
You may not be eligible if your doctors have determined that drug-based treatment is not suitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Manuela Ianni, Ospedale S. Orsola-Malpighi

Phone: +390512142207

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06863805

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase: Not Applicable

Status: Recruiting

Condition: Thyroid Cancer

Trial contact: +390512142207

More information: https://clinicaltrials.gov/study/NCT06863805

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be willing and able to sign a consent form agreeing to take part in the study
You must be an adult aged 18 or older (male or female)
You must have been diagnosed with advanced thyroid cancer, confirmed by a central review of tissue samples
Your thyroid cancer must be one of the following types: well-differentiated thyroid cancer, medullary thyroid cancer, or anaplastic thyroid cancer — and it must be at a stage where doctors are considering starting drug-based treatment
A genetic analysis of your tumor tissue must have already been carried out using a specific type of advanced molecular testing (confirm with trial site)
Your cancer must be measurable on standard imaging scans, such as a CT scan with contrast dye, or a PET-CT scan

Who may not be able to join:

You may not be eligible if you have already received any previous drug-based treatments for your thyroid cancer
You may not be eligible if your doctors have determined that drug-based treatment is not suitable for you

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Registry

ClinicalTrials.gov

Start date

15 December 2022

Est. completion

31 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Genomic alterations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov